2025 - IRIS CAPITAL INVESTMENT

30 Apr 25

Plant Advanced Technologies Releases 2024 Annual Results

Vandoeuvre lès Nancy, France – Apr 29 2025 – 2024 annual results: • First positive operating profit since PAT’s creation in 2005: €215,000 compared to a loss of €778,000 in 2023• Strong increase in net profit to €935,000 (48% of revenue) compared to €79,000 in 2023• Outlook: Confirmation of the…

17 Apr 25

Oncodesign Precision Medicine announces the establishment of an equity financing line of up to €5 million

Dijon, France – apr 17, 2025 – Oncodesign Precision Medicine, a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces the establishment of an equity financing line of up to €5 million. DOWNLOAD Oncondesign press release (french) Dijon, France, le 17 avril 2025 – …

17 Apr 25

IRIS Capital invests in SYNBIOTIC’s growth strategy

Düsseldorf, Germany– apr 17, 2025 – The European medical cannabis and industrial hemp group SYNBIOTIC SE and the venture capital company IRIS Capital Investment have entered into a strategic partnership. The French investment company will actively support SYNBIOTIC’s growth strategy. In a first phase, IRIS Capital Investment has decided and…

27 Mar 25

CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment

Paris, France – mar 27, 2025 – CARMAT, designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure , announces the implementation of a flexible equity financing line with IRIS Capital Investment (“IRIS”), for a…

24 Jan 25

Median Technologies Secures up to €10 million equity line completed with IRIS to enable 2025 EIB loan

Sophia Antipolis, France – jan 24, 2025 – Median Technologies a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI analyses and imaging services for oncology drug developers announces up to €10…

Year: 2025

Plant Advanced Technologies Releases 2024 Annual Results

Oncodesign Precision Medicine announces the establishment of an equity financing line of up to €5 million

IRIS Capital invests in SYNBIOTIC’s growth strategy

CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment

Median Technologies Secures up to €10 million equity line completed with IRIS to enable 2025 EIB loan

Links